Boehringer Ingelheim exercised its option to acquire global rights to anti-inflammatory candidate PXS4728A and related molecules from Pharmaxis Ltd. Boehringer plans to develop the oral vascular adhesion protein-1 inhibitor to treat non-alcoholic steatohepatitis (NASH). The compound is in a Phase I study to treat inflammatory disease.